BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

The Day In Review: Hollis-Eden Pharmaceuticals Inc. (HEPH) Loses Stockpile Contract For Neumune


3/8/2007 5:45:06 PM

March 8, 2007 -- Hollis-Eden Pharma was refused a contract by the HHS to supply radiation drug Neumune to the biodefense stockpile; LaJolla Pharma released positive data from a Phase III trial of Riquent for lupus; Barrier Therapeutics received approval to market Xolegel for seborrheic dermatitis in Canada; Myriad Genetics began a Phase II trial of Azixa in patients with brain cancer; Pfizer received FDA approval of five new indications for Lipitor; OncoGenex withdrew its application for an IPO; and Immune Response said the first patient in a Phase II trial received NeuroVax for MS. The Centient Biotech 200™ closed with a 10-point gain at 3828, a rise of .27%. More details...

Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->